{"id":"belotecan","rwe":[],"tags":[{"label":"belotecan","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"DNA topoisomerase 1","category":"target"},{"label":"TOP1","category":"gene"},{"label":"L01CE04","category":"atc"},{"label":"Active","category":"status"},{"label":"Malignant tumor of ovary","category":"indication"},{"label":"Non-small cell lung cancer","category":"indication"},{"label":"Chong Kun Dang","category":"company"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Topoisomerase I Inhibitors","category":"pharmacology"},{"label":"Topoisomerase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Chong Kun Dang","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BELOTECAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:16:22.834476+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:16:29.468390+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BELOTECAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:16:30.235354+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA topoisomerase I inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:30.878382+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2111084/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:30.705950+00:00"}},"allNames":"camtobell","offLabel":[],"synonyms":["belotecan","camtobell","belotecan hydrochloride","CKD602","CKD-602"],"timeline":[{"date":"2003-12-10","type":"positive","source":"DrugCentral","milestone":"Korean Food and Drug Administration (KFDA) approval (Chong Kun Dang)"}],"brandName":"Camtobell","ecosystem":[{"indication":"Malignant tumor of ovary","otherDrugs":[{"name":"altretamine","slug":"altretamine","company":"Eisai Inc"},{"name":"carboplatin","slug":"carboplatin","company":""},{"name":"cisplatin","slug":"cisplatin","company":"Hq Spclt Pharma"},{"name":"doxorubicin","slug":"doxorubicin","company":""}],"globalPrevalence":null},{"indication":"Non-small cell lung cancer","otherDrugs":[{"name":"alectinib","slug":"alectinib","company":"Hoffman-La Roche"},{"name":"brigatinib","slug":"brigatinib","company":"Ariad"},{"name":"ceritinib","slug":"ceritinib","company":"Novartis Pharms Corp"},{"name":"crizotinib","slug":"crizotinib","company":"Pf Prism Cv"}],"globalPrevalence":2200000}],"mechanism":{"target":"DNA topoisomerase 1","targets":[{"gene":"TOP1","source":"DrugCentral","target":"DNA topoisomerase 1","protein":"DNA topoisomerase 1"}],"modality":"Small Molecule","drugClass":"belotecan","explanation":"","oneSentence":"","technicalDetail":"Belotecan acts as a competitive inhibitor of DNA topoisomerase 1, preventing the enzyme from relaxing supercoiled DNA and thereby inducing DNA damage and apoptosis in cancer cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/296","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BELOTECAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BELOTECAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:50:06.500327","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:32.839756+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"topotecan","drugSlug":"topotecan","fdaApproval":"1996-05-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"irinotecan","drugSlug":"irinotecan","fdaApproval":"1996-06-14","patentExpiry":"Oct 15, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"belotecan","indications":{"approved":[{"name":"Malignant tumor of ovary","source":"DrugCentral","snomedId":363443007,"regulator":"FDA"},{"name":"Non-small cell lung cancer","source":"DrugCentral","snomedId":254637007,"regulator":"FDA","usPrevalence":236000,"globalPrevalence":2200000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"topotecan","brandName":"topotecan","genericName":"topotecan","approvalYear":"1996","relationship":"same-class"},{"drugId":"irinotecan","brandName":"irinotecan","genericName":"irinotecan","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00826644","phase":"PHASE3","title":"Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2009-01","conditions":["Carcinoma, Small Cell"],"enrollment":147,"completionDate":"2013-02"},{"nctId":"NCT01497873","phase":"PHASE2","title":"A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2010-09","conditions":["Small Cell Lung Cancer"],"enrollment":164,"completionDate":"2018-03"},{"nctId":"NCT01630018","phase":"PHASE2","title":"Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-01","conditions":["Epithelial Ovarian Cancer"],"enrollment":141,"completionDate":"2014-06"},{"nctId":"NCT01784107","phase":"PHASE1,PHASE2","title":"A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Gachon University Gil Medical Center","startDate":"2011-07","conditions":["Small Cell Lung Cancer"],"enrollment":45,"completionDate":""},{"nctId":"NCT01022671","phase":"PHASE2","title":"Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2009-09","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":52,"completionDate":"2010-03"},{"nctId":"NCT00754858","phase":"PHASE2","title":"Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2008-10","conditions":["Lung Cancer"],"enrollment":42,"completionDate":"2012-06"},{"nctId":"NCT00177281","phase":"PHASE1","title":"Safety Study of S-CKD602 in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-09","conditions":["Cancer"],"enrollment":45,"completionDate":"2006-05"},{"nctId":"NCT00430144","phase":"PHASE2","title":"Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix","status":"COMPLETED","sponsor":"Sokbom Kang","startDate":"2007-01","conditions":["Cervical Cancer"],"enrollment":16,"completionDate":"2010-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"27Z82M2G1N","CHEBI":"CHEBI:135702","INN_ID":"8483","UMLSCUI":"C0762737","chemblId":"CHEMBL2111084","ChEMBL_ID":"CHEMBL2111084","KEGG_DRUG":"D03225","DRUGBANK_ID":"DB12459","PUBCHEM_CID":"6456014","SECONDARY_CAS_RN":"213819-48-8","MESH_SUPPLEMENTAL_RECORD_UI":"C116963"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Chong Kun Dang","relationship":"Current Owner"}],"publicationCount":57,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01CE04","allCodes":["L01CE04"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Chong Kun Dang","companyId":"chong-kun-dang","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camptothecin (belotecan) is a small molecule inhibitor that targets DNA topoisomerase 1. It has been studied in clinical trials for various types of cancer, including lung cancer and ovarian cancer, often in combination with other treatments such as cisplatin.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:32.839756+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}